Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00844181 · ClinicalTrials.gov registry record
Racial Differences in Orthostatic Tolerance
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 18
- Enrollment target
NCT00844181: Completed study, sponsored by Yale University.
NCT00844181 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00844181 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
Our central hypothesis is that baroreflex sensitivity is attenuated in black women compared to white women, and that this dysregulation will be apparent during orthostatic challenges. We expect that the cumulative stress index (CSI), a measure of maximal orthostatic tolerance, is higher in Black women (BW) compared to White women (WW).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-01 |
What the finished NCT00844181 record still lists
NCT00844181 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00844181 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00844181 about?
NCT00844181 is a clinical study titled "Racial Differences in Orthostatic Tolerance". Our central hypothesis is that baroreflex sensitivity is attenuated in black women compared to white women, and that this dysregulation will be apparent during orthostatic challenges. We expect that the cumulative stress index (CSI), a measure of maximal orthostatic tolerance, is higher in Black wom...
What is the current status of trial NCT00844181?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2007-10. Estimated completion is 2009-01.
Who is sponsoring clinical trial NCT00844181?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia